Cervical cancer is a type of cancer that develops in women’s cervix and mainly affects sexually active women aged between 30 and 45. Cervical cancer doesn’t show any symptoms at the initial phase. Cervical cancer can be diagnosed by using a Pap test (Papanicolaou test), which is a screening test that can identify the changes taking place in the cervix before the development of cancer. The most common type of cervical cancer is squamous cell cancer and adenocarcinoma.
Request for Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1746
The rising number of drug approval done by the U.S. Food and Drug Administration (FDA) for the treatment of cervical cancer is projected to drive the growth of the cervical cancer drug market over the forecast period. For instance, in September 2017, U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, which includes cervical, lung, brain, colorectal and kidney cancer. Mvasi is indicated for use in persistent, recurrent, or metastatic cervical cancer. In August 2014, the U.S. FDA approved Genentech’s Avastin, which is bevacizumab solution for intravenous infusion in combination with paclitaxel for the treatment of persistent, recurrent, or metastatic cervical cancer.
Furthermore, rising funding for cancer research, improving insurance coverage, and growth in the number of new targeted cancer drugs are expected to support the revenue growth of the cervical cancer drugs market. For instance, National Cancer Institute, in 2015, spent around US$ 4,480 million on cancer research, which includes cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, ovarian cancer, and uterine cancer. Furthermore, according to the American Cancer Society, the U.S. invested around US$ 87.8 billion in 2014 on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.
Apply Promo Code “STAYHOME” and Get Instant Discount of USD 1000
If you purchase the report this year:
Flat 20% instant discount
25% discount on 2nd report
15 % free customization
Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/1746
Some of the key players operating in the cervical cancer drugs market include F. Hoffmann-La Roche Ltd., Hetero, GlaxoSmithKline, plc, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., AstraZeneca plc, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company, and Novartis AG. Key players operating in the market are focused on organic growth strategies, in order to enhance their market share and retain their competence in the market.
For instance, in July 2014, MedImmune: a biologics research and development division of AstraZeneca entered into a clinical trial collaboration with Advaxis. According to the agreement, both companies conducted Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor: MEDI4736, in combination with Advaxis’ cancer immunotherapy vaccine: ADXS-HPV. This study is conducted to develop a treatment for patients with advanced, recurrent or refractory Human Papillomavirus (HPV)-associated cervical cancer.
Direct Line: +1-206-701-6702 (US)